Evidence map›Paper›PMID 35770949›Full record

ArticleCancer medicine2023

EphrinA3 is a key regulator of malignant behaviors and a potential prognostic factor in lung adenocarcinoma.

Ruzetuoheti Yiminniyaze, Xiujuan Zhang, Ning Zhu, Jing Wang, Chengwei Li, Gulinuer Wumaier, Daibing Zhou, Jing Li, Jingwen Xia, Youzhi Zhang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?International journal of molecular sciences · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ruzetuoheti YiminniyazeDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-9403-9613
Xiujuan ZhangDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Ning ZhuDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Jing WangDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Chengwei LiDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Gulinuer WumaierDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Daibing ZhouDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Jing LiDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Jingwen XiaDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Youzhi ZhangDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Liang DongDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Yuanyuan ZhangDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Shengqing LiDepartment of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs a member of the Ephrin protein family that elicits short distance cell-cell signaling, EphrinA3 has been shown to promote or inhibit tumorigenesis depending on tumor types, but its roles and the underlying mechanisms in lung adenocarcinoma (LUAD) have not been reported. MATERIALS AND

methodsThe TCGA database and Kaplan-Meier Plotter database were used to analyze the differential expression of EphrinA3 between LUAD and para-carcinoma tissues, and its effect on overall survival of LUAD patients. CCK-8 assay, Edu assay, and flow cytometry were used to probe the effect of EphrinA3 on the proliferation of LUAD cells, and transwell assay was employed to examine its effect on migration and invasion. In addition, the effect of EphrinA3 on the growth of LUAD was further evaluated using a xenograft tumor model.

resultsEphrinA3 was expressed highly in LUAD, and its expression level was negatively correlated with the prognosis of LUAD patients. In addition, EphrinA3 promoted proliferation, migration, and invasion of LUAD cells, and accelerated tumor growth in a xenograft LUAD model. The reported EphrinA3 receptors, EphA1 and EphA10, were expressed in clinical LUAD tissues and co-localized with EphrinA3 in LUAD cells. Mechanistically, EphrinA3/Eph signaling activated AKT, ERK, and p38MAPK, induced epithelial-mesenchymal transition (EMT), and upregulated matrix metalloproteases-2 and -9 (MMP-2/-9).

conclusionEphrinA3 expression was negatively correlated with prognosis of patients with LUAD. EphrinA3 promoted proliferation, migration, and invasion of LUAD cells. EphrinA3 enhanced the phosphorylation of ERK and AKT, and potentiates EMT and MMP expression in LUAD cells.

Indexed as

Adenocarcinoma of LungLung NeoplasmsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansPrognosisProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-aktcancer biologyephrinA3lung adenocarcinomaPI3K/Akt signaling

Identifiers

PMID35770949
PMCPMC9883548
OpenAlexW4283743135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.